Ledipasvir is a potent HCV NS5A inhibitor that has revolutionized the treatment of chronic hepatitis C. As part of the fixed-dose combination with sofosbuvir (Harvoni®), Ledipasvir offers a highly effective, well-tolerated, and short-duration therapy for patients with HCV genotype 1 infection. Ledipasvir inhibits the NS5A protein, which is essential for viral RNA replication and the assembly of HCV virions. Ledipasvir is effective against HCV genotypes 1a, 1b, 4a, and 5a, with lesser activity against genotypes 2a and 3a. Importantly, Ledipasvir exhibits a high barrier to resistance development compared to other classes of HCV drugs. In joint recommendations from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), Ledipasvir in combination with sofosbuvir is recommended as a first-line therapy for HCV genotypes 1, 4, 5, and 6.
Product Parameters
|
Parameter |
Specification |
|
Product Name |
Ledipasvir |
|
CAS Number |
1256388-51-8 |
|
Molecular Formula |
|
|
Molecular Weight |
|
|
Physical Form |
Solid powder |
|
Appearance |
White to off-white powder |
|
Storage Condition |
-20°C |
Bioactivity
Why Cosperpharm?
Quality you can trust. Our Ledipasvir is released with comprehensive analytical characterization including HPLC purity verification (≥98%), NMR structural confirmation, and mass spectrometry identity confirmation. Every batch is accompanied by a Certificate of Analysis with full chromatographic traceability.
Documentation for regulatory submission. As a key NS5A inhibitor API, Ledipasvir requires rigorous documentation for regulatory filings. Every shipment includes a COA with batch-specific purity data, an SDS, and customs documentation. DMF-ready documentation packages and custom quality agreements are available upon request.
Flexible supply across all development stages. Cosperpharm supplies Ledipasvir from milligram quantities for analytical method development and screening to gram-scale and kilogram-scale batches for process development and commercial manufacturing.
Technical expertise in complex antiviral synthesis. Our team understands the synthetic challenges of the complex benzimidazole-fluorene scaffold and can provide technical support for your Ledipasvir-related projects.
Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and research institutions worldwide. Volume discounts apply and we communicate lead times upfront.
Product Advantages
Ledipasvir is a highly potent inhibitor of the HCV NS5A protein, a critical component for viral RNA replication and virion assembly. Its high affinity for NS5A underlies the exceptional efficacy of the ledipasvir/sofosbuvir combination in achieving sustained virologic response (SVR) rates exceeding 90%.
Broad Genotypic Coverage
Ledipasvir is effective against multiple HCV genotypes, including genotypes 1a, 1b, 4a, and 5a. This broad activity makes it a versatile component of HCV therapy across diverse patient populations.
High Barrier to Resistance
Compared to HCV protease inhibitors, Ledipasvir exhibits a higher barrier to the development of resistance, an important advantage in preventing therapeutic failure.
First-Line Therapy Status
Ledipasvir in combination with sofosbuvir is recommended as first-line therapy by AASLD/IDSA guidelines for HCV genotypes 1, 4, 5, and 6, reflecting its established efficacy and safety profile.
Well-Tolerated with Minimal Side Effects
Treatment with Ledipasvir is associated with very minimal side effects, with the most common being headache and fatigue. The lack of significant side effects and short duration of therapy (12 weeks) represent considerable advantages over older interferon- and ribavirin-based regimens.
Product Advantages
Ledipasvir is a highly potent inhibitor of the HCV NS5A protein, a critical component for viral RNA replication and virion assembly. Its high affinity for NS5A underlies the exceptional efficacy of the ledipasvir/sofosbuvir combination in achieving sustained virologic response (SVR) rates exceeding 90%.
Broad Genotypic Coverage
Ledipasvir is effective against multiple HCV genotypes, including genotypes 1a, 1b, 4a, and 5a. This broad activity makes it a versatile component of HCV therapy across diverse patient populations.
High Barrier to Resistance
Compared to HCV protease inhibitors, Ledipasvir exhibits a higher barrier to the development of resistance, an important advantage in preventing therapeutic failure.
First-Line Therapy Status
Ledipasvir in combination with sofosbuvir is recommended as first-line therapy by AASLD/IDSA guidelines for HCV genotypes 1, 4, 5, and 6, reflecting its established efficacy and safety profile.
Well-Tolerated with Minimal Side Effects
Treatment with Ledipasvir is associated with very minimal side effects, with the most common being headache and fatigue. The lack of significant side effects and short duration of therapy (12 weeks) represent considerable advantages over older interferon- and ribavirin-based regimens.
Storage Conditions
Handling precautions: Use in a fume hood. Wear appropriate personal protective equipment including gloves, safety goggles, and a lab coat. Avoid generating dust. Refer to the Safety Data Sheet (SDS) for complete safety information.
Contact Us
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
